Viridian Therapeutics Reports Positive VRDN-008 Phase 1 Results
The company said the results showed sustained IgG reduction and supported potential every-eight-week dosing. It plans a pivotal trial in 2027.
Viridian Therapeutics reported positive Phase 1 results for VRDN-008, showing sustained IgG reduction and supporting potential every-eight-week dosing.Key Highlights:Original SEC Filing: Viridian Therapeutics, Inc.\DE [ VRDN ] - 8-K - Nov. 09, 2026This is an AI-powered summary. It may contain inacc…